» Articles » PMID: 35219542

Global Challenges in Breast Cancer Detection and Treatment

Overview
Journal Breast
Publisher Elsevier
Specialties Endocrinology
Oncology
Date 2022 Feb 27
PMID 35219542
Authors
Affiliations
Soon will be listed here.
Abstract

Breast cancer represents an urgent global priority. While this is a universal issue, and as the burden of the disease is increasing globally, current estimates indicate that in the next couple of decades, much of the incidence and mortality related to breast cancer will be seen in underserved populations. The fragile and ill-prepared healthcare systems in low- and middle-income countries (LMIC) need to address this challenge and find solutions with their limited resources. Significant disparities can be identified in stage at presentation as the ability to detect the disease in earlier stages is compromised in these scenarios leading to worse outcomes associated to late diagnoses. Furthermore, access to healthcare in general and to basic surgical, radiotherapy and systemic care is suboptimal additionally limiting treatment results. With a small portion of their budget allocated to healthcare, LMIC need to make the most of their resources prioritizing cost-effective strategies that could offer the best possible results. Countries that invest in women's health do develop into healthier, more educated, and importantly, more productive societies with benefits seen across generations. Finally, recognition of inequities should stimulate a concerted effort engaging all involved stakeholders to find context-adapted solutions to improve healthcare outcomes.

Citing Articles

Outcomes and Current State of Deep Inferior Epigastric Perforator Flap Surgery in Peru and Mexico.

Ziegler Rodriguez O, De La Cruz-Ku G, Ludena Munoz J, Rodriguez Valdivia J, Ramos-Acevedo C, Medina Flores E Plast Reconstr Surg Glob Open. 2025; 13(2):e6532.

PMID: 39995477 PMC: 11850047. DOI: 10.1097/GOX.0000000000006532.


Understanding the Electrochemical MOF Sensors in Detecting Cancer with Special Emphasis on Breast Carcinoma Biomarkers.

Mohan B, Modi K, Singh G, Paul A, Garazade I, Pombeiro A Top Curr Chem (Cham). 2025; 383(1):9.

PMID: 39966301 DOI: 10.1007/s41061-025-00493-0.


Effects of BMI on prognosis, disease-free survival and overall survival of breast cancer.

Zangouri V, Balaneji S, Golmoradi R, Kafili E, Bologhi S, Mousavi S BMC Cancer. 2025; 25(1):257.

PMID: 39948483 PMC: 11827321. DOI: 10.1186/s12885-025-13638-7.


A review of six bioactive compounds from preclinical studies as potential breast cancer inhibitors.

Rampogu S, Al-Antari M, Oh T, Shaik B Mol Biol Rep. 2025; 52(1):203.

PMID: 39907697 DOI: 10.1007/s11033-025-10300-0.


Anti-tumor Effects of Recombinant Clostridium α-Toxin on Breast Cancer: An and Study.

Rezaei Khozani N, Shayesteh Pour M, Yekani M, Hejazi S, Saffari M Int J Mol Cell Med. 2025; 13(4):404-416.

PMID: 39895919 PMC: 11786122. DOI: 10.22088/IJMCM.BUMS.13.4.404.


References
1.
Shao J, Rodrigues M, Corter A, Baxter N . Multidisciplinary care of breast cancer patients: a scoping review of multidisciplinary styles, processes, and outcomes. Curr Oncol. 2019; 26(3):e385-e397. PMC: 6588064. DOI: 10.3747/co.26.4713. View

2.
Carioli G, Malvezzi M, Rodriguez T, Bertuccio P, Negri E, La Vecchia C . Trends and predictions to 2020 in breast cancer mortality in Europe. Breast. 2017; 36:89-95. DOI: 10.1016/j.breast.2017.06.003. View

3.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

4.
Barrios C, Freitas-Junior R, Martins S, Bines J, Estevez-Diz M, Caleffi M . Challenge of Incorporating New Drugs for Breast Cancer in Brazil: A Proposed Framework for Improving Access to Innovative Therapies. JCO Glob Oncol. 2021; 7:474-485. PMC: 8081546. DOI: 10.1200/GO.20.00566. View

5.
Harford J . Breast-cancer early detection in low-income and middle-income countries: do what you can versus one size fits all. Lancet Oncol. 2011; 12(3):306-12. DOI: 10.1016/S1470-2045(10)70273-4. View